Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the very first-line remedy of CML-CP. Five hundred and nineteen people with freshly diagnosed CML-CP were randomly assigned to get dasatinib at a dose of 100 mg once each day (259 individuals) or imatinib at https://dabrafenib-mesylate02457.affiliatblogger.com/81008626/a-review-of-itd-1